PTH and Hypercalcemia: Clinical practice guidelines recommend calcium as first line treatment for stages 4 and 5 CKD patients [9, 10] and suggest that serious gastrointestinal side effects, hypercalcemia and low parathyroid hormone at the lowest extreme (<100 pg/ml for hemodialysis patients) are main indications for a switch to NCBPs or a combination treatment [48, 74].